Sign In

Dana Cohen

Diagknowstics, Founder | ZOTAL, Head of Personalized & Predictive diagnostics, | Director at Protica Bio | Partner at ARION

Dana Cohen is a prominent figure in the biotech industry, recognized for her role as the Founder and CEO of BioMe. YOU. In a capsule. With over 25 years of experience, she has held various executive positions, including her current leadership at DiagKnowstics, where she also serves as CEO.12

Cohen's expertise spans personalized and predictive medicine, biotechnology, and commercialization in the pharmaceutical sector. Her career reflects a strong commitment to innovation in healthcare, leveraging her extensive background to drive advancements in medical technology.123

In addition to her entrepreneurial ventures, Cohen has been involved in academic research and holds a degree from The Hebrew University, further enhancing her credentials in the biotech field.2

Highlights

May 23 · linkedin

Proud to partner with PROTICA BIO, presenting at the Liquid Biopsy & Diagnostics session at BIOMED ISREAL PROTICA develops novel signature predicting response to immunotherapy treatment based on unprecedented protein coverage of 11K tissue proteins. . Treatment with immune checkpoint inhibitors mainly anti-PD1, has revolutionized oncological therapy for selected patients. However, the response rates are still significantly lower. PRPTICA Bio is combining state-of-the-art proteomics and computational biology. The leading pipeline indication is Head & Neck cancer, currently with only 15-20% response rate to immunotherapy. PROTICA completed its POC study on 121 FFPE biopsies.  https://www.protica.bio/

May 21 · linkedin

Ratuximab (Mabthera) – Can we optimize treatment? In 2022 the industry size of Rituximab (Mabthera) was over 3Bn, mostly controlled by 6 global pharma. Can this blockbuster drug be dosed correctly to ensure that patients will maintain an optimal and effective therapeutic drug level? what about monitoring immunogenicity (antibodies against the drug)? Rituximab is a biological drug and is intended for the treatment of CLL leukemia, non-Hodgkin's lymphoma, follicular lymphoma, rheumatoid arthritis (in combination with methotrexate) and for the treatment of ANCA. A personalized treatment of Rituximab would require a simple Pharmacokinetic analysis of each patient using a standard ELISA test that could lead to dose rescheduling.  A simple blood test can change the practice. Different types of cancer are treated with rituximab as monotherapy or in combination with other chemotherapy drugs. Monitoring blood levels of the drug (known as TDM) and monitoring the level of antibodies against the drug can help hemato-oncologists and rheumatologists direct treatment and diagnose immunogenicity. Here are a few examples from the literature following the integration of  TDM in the standard routine:

  1. Approximately 10.6% of Rheumatology patients develop immunogenicity and anti-drug antibodies and are at risk of relapse
  2. There is a very large variability between patients (order of magnitude 1) in the blood concentration and drug clearance (mainly in maintenance treatments).
  3. The pharmacokinetics of RTX is highly correlated with clinical response and can be used as a predictive marker (Rozman S, 2017)
  4. In nephrological and rheumatological diseases there is a relationship between high RTX levels in the serum after 90 days and the percentage of remission after 180 days.
  5. In DLBCL lymphoma patients, a high dose of RTX in adult men (500mg) improved prognosis and survival rates without increasing toxicity. (M Pfreundschuh, 2017)
  6. In DLBCL patients, exposure to RTX decreases when the tumor is large (according to PET). In patients with serum drug levels of 9400mg/h/L, there was a better response also in the survival indices tested. (Tout M 2017) PFS, OS
  7. In Non-Hodgkin's lymphoma patients, the effect of age, sex and body mass on clinical outcomes of 303 patients was examined. A suboptimal dose can be adjusted in under dosed patients. (Sawalha Y 2016)
  8. Clearance of rituximab is low in women (their weight is lower) and increases according to weight, therefore on average men are less exposed to effective treatment.
  9. Drug trough levels higher than 25ng/ml in lymphoma patients may predict a risk of disease recurrence (Ulrich J, 2012, Haematologica)

Along with determination of appropriated therapeutic windows taking into account ADAs content, treatment algorithms for TDM-guided clinical decision-making must be developed and prospectively shown to be superior to traditional clinical care for each mAb in each indication.

Related Questions

What is the main focus of BioMe. YOU. In a capsule?
How did Dana Cohen transition from BioMe to DiagKnowstics?
What are some notable achievements of Dana Cohen in the biotech industry?
What inspired Dana Cohen to start her career in biotechnology?
How has Dana Cohen's experience in corporate fashion influenced her biotech career?
Dana Cohen
Dana Cohen, photo 1
Dana Cohen, photo 2
Add to my network

Location

Tel Aviv-Yafo, Tel Aviv District, Israel